(VIANEWS) - New York Mortgage Trust (NYMT), Halozyme Therapeutics (HALO), Option Care Health (OPCH) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. New York Mortgage Trust (NYMT)
78.3% sales growth and 12.73% return on equity
New York Mortgage Trust, Inc. acquires, invests in, finances, and manages mortgage-related single-family and multi-family residential assets in the United States.
New York Mortgage Trust's sales growth this year is anticipated to be 24.4% and 22.5% for next year.
Year-on-year quarterly revenue growth declined by 44.9%, now sitting on 353.88M for the twelve trailing months.
Volume
Today's last reported volume for New York Mortgage Trust is 2280300 which is 22.44% below its average volume of 2940230.
New York Mortgage Trust's sales growth for the next quarter is 78.3%. The company's growth estimates for the current quarter and the next is a negative 60.7% and negative -52.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.73%.
Volatility
New York Mortgage Trust's last day, last week, and last month's current volatility was 0.68%, 0.91%, and 0.91%, respectively.
New York Mortgage Trust's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.38% (day), 1.56% (last week), and 1.81% (last month), respectively.
New York Mortgage Trust's Stock Yearly Top and Bottom Value
New York Mortgage Trust's stock is valued at $4.38 at 20:22 EST, way below its 52-week high of $4.93 and way above its 52-week low of $2.40.
New York Mortgage Trust's Moving Average
New York Mortgage Trust's worth is above its 50-day moving average of $4.35 and under its 200-day moving average of $4.45.2. Halozyme Therapeutics (HALO)
63.8% sales growth and 259.61% return on equity
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
Halozyme Therapeutics's sales growth this year is anticipated to be 64.7% and 34.1% for next year.
Year-on-year quarterly revenue growth grew by 251.1%, now sitting on 331.26M for the twelve trailing months.
Volume
Today's last reported volume for Halozyme Therapeutics is 505248 which is 37.24% below its average volume of 805134.
Halozyme Therapeutics's sales growth for the next quarter is 63.8%. The company's growth estimates for the current quarter and the next is 115.8% and 68%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 259.61%.
Volatility
Halozyme Therapeutics's last day, last week, and last month's current volatility was 1.40%, 0.71%, and 1.47%, respectively.
Halozyme Therapeutics's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.05% (day), 1.86% (last week), and 3.51% (last month), respectively.
Halozyme Therapeutics's Stock Yearly Top and Bottom Value
Halozyme Therapeutics's stock is valued at $42.22 at 20:22 EST, way below its 52-week high of $56.40 and way above its 52-week low of $25.17.
Halozyme Therapeutics's Moving Average
Halozyme Therapeutics's value is higher than its 50-day moving average of $41.16 and under its 200-day moving average of $43.56.3. Option Care Health (OPCH)
22.6% sales growth and 5.04% return on equity
Option Care Health, Inc. offers home and alternate site infusion services in the United States.
Option Care Health's sales growth this year is expected to be 12.5% and 7.7% for next year.
Year-on-year quarterly revenue growth grew by 16.1%, now sitting on 3.21B for the twelve trailing months.
Volume
Today's last reported volume for Option Care Health is 1004560 which is 53.96% below its average volume of 2182010.
Option Care Health's sales growth for the next quarter is 22.6%. The company's growth estimates for the ongoing quarter and the next is 325% and 1800%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.04%.
Volatility
Option Care Health's last day, last week, and last month's current volatility was 1.20%, 2.40%, and 2.34%, respectively.
Option Care Health's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.13% (day), 3.91% (last week), and 3.91% (last month), respectively.
Option Care Health's Stock Yearly Top and Bottom Value
Option Care Health's stock is valued at $27.86 at 20:22 EST, under its 52-week high of $27.97 and way higher than its 52-week low of $10.52.
Option Care Health's Moving Average
Option Care Health's worth is way higher than its 50-day moving average of $22.66 and way above its 200-day moving average of $20.22.Previous days news about Option Care Health(OPCH)
- Option care health announces secondary offering of 9,200,000 shares of common stock. According to GlobeNewsWire on Tuesday, 7 September, "As a result, Walgreens will maintain its approximately 21% indirect financial interest in Option Care Health following this offering.", "Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates."
4. Installed Building Products (IBP)
22.5% sales growth and 34.76% return on equity
Installed Building Products, Inc., together with its subsidiaries, engages in the installation of insulation, waterproofing, fire-stopping, fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving and mirrors, and other products in the continental United States.
Installed Building Products's sales growth this year is anticipated to be 18.9% and 11.2% for next year.
Year-on-year quarterly revenue growth grew by 23.9%, now sitting on 1.79B for the twelve trailing months.
Volume
Today's last reported volume for Installed Building Products is 83360 which is 60.28% below its average volume of 209889.
Installed Building Products's sales growth for the next quarter is 22.5%. The company's growth estimates for the ongoing quarter and the next is 31.2% and 36.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 34.76%.
Volatility
Installed Building Products's last day, last week, and last month's current volatility was 1.38%, 1.10%, and 1.38%, respectively.
Installed Building Products's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.68% (day), 1.89% (last week), and 2.66% (last month), respectively.
Installed Building Products's Stock Yearly Top and Bottom Value
Installed Building Products's stock is valued at $120.95 at 20:22 EST, way under its 52-week high of $140.58 and way higher than its 52-week low of $85.18.
Installed Building Products's Moving Average
Installed Building Products's value is under its 50-day moving average of $121.41 and higher than its 200-day moving average of $119.41.5. Verisk Analytics (VRSK)
9.4% sales growth and 29.23% return on equity
Verisk Analytics, Inc. provides data analytics solutions in the United States and internationally.
Verisk Analytics's sales growth this year is expected to be 7.6% and 6.6% for next year.
Year-on-year quarterly revenue growth grew by 5.3%, now sitting on 2.82B for the twelve trailing months.
Volume
Today's last reported volume for Verisk Analytics is 1024370 which is 24.84% above its average volume of 820514.
Verisk Analytics's sales growth for the next quarter is 9.4%. The company's growth estimates for the ongoing quarter and the next is 3.1% and 3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.23%.
Volatility
Verisk Analytics's last day, last week, and last month's current volatility was 0.23%, 0.55%, and 0.63%, respectively.
Verisk Analytics's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.16% (day), 1.20% (last week), and 1.32% (last month), respectively.
Verisk Analytics's Stock Yearly Top and Bottom Value
Verisk Analytics's stock is valued at $203.11 at 20:22 EST, under its 52-week high of $210.66 and way above its 52-week low of $159.79.